We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2026-01-21 Redeye Theme Event Fight Cancer

2026-01-21 Redeye Theme Event Fight Cancer

David Liberg, CSO Cantargia, presents at Redeye Theme Event Fight Cancer 202

Watch the presentation here

2025-10-07 Interview with BioStock

Interview with CEO Hilde H. Steineger

Watch the interview here

2025-10-07 Interview with BioStock

2025-10-01Interview with Redeye

2025-10-01Interview with Redeye

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference

Watch the interview here

Press releases

2026-01-23 Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study

2025-12-05 (R) Cantargia Provides Update on Overall Survival Data from TRIFOUR

2025-11-19 (R) Cantargia Publishes Interim Report for January to September 2025

(R) = Regulatory press releases

Analysis

2025-12-05 Redeye analysis of Cantargia

2025-07-18, Redeye analysis of Cantargia

2025-07-15, Redeye analysis of Cantargia

2025-06-11, Redeye analysis of Cantargia

Current corporate presentation

Download the corporate presentation as PDF

Other presentations

2026-01-21, Video, Redeye Theme Event Fight Cancer 2026

2025-12-03, Video, Redeye Life Science Day 2025

2025-11-20, Video, PALEMA Världspankreascancerdagen 2025 (In Swedish)

2025-11-19, Video, Redeye Theme Event Autoimmune & Inflammatory Diseases

2025-11-17, Video, BioStock Life Science Summit